Abstract

BackgroundAccording to the 2012 ACR guidelines (1) anti-inflammatory prophylaxis is recommended when urate lowering drugs (ULDs) are initiated and should be continued if there is continuing gout activity and/or serum...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Gout Prophylaxis Evaluated According to the 2012 American College of Rheumatology Guidelines: Analysis from the CORRONA Gout Registry.
Jeff Greenberg ... Leslie R Harrold
The Journal of rheumatology | VOL. 43
Jeff Greenberg, et. al.Jeff Greenberg ... Leslie R Harrold
15 Mar 2016
Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients.
Alan R Erickson ... Sterling G West
Arthritis and rheumatism | VOL. 38
Alan R Erickson, et. al.Alan R Erickson ... Sterling G West
01 Aug 1995
Hitting the target in gout.
The Lancet Rheumatology
The Lancet. Rheumatology | VOL. 2
The Lancet Rheumatology The Lancet Rheumatology
01 Jan 2020
Time to update guidelines on screening for latent tuberculosis infection in dermatologic patients being treated with tumor necrosis factor-alfa inhibitors
Karynne O Duncan
Journal of the American Academy of Dermatology | VOL. 72
Karynne O DuncanKarynne O Duncan
13 Mar 2015
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers